An ongoing phase I clinical trial (NCT03293784) is evaluating the safety and tolerability of treating metastatic melanoma patients with immune checkpoint blockade in combination with the anti-TNF blocking agents infliximab and certolizumab and is expecting to mitigate or avoid irAEs while augmenting antitumor efficacy. This evidence concerns the gene TNF and metastatic melanoma.